If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
=== United States === Ochoa then went to the United States, where he again held many positions at several universities. Between 1940 and 1942, Ochoa worked for Washington University's School of Medicine. In 1942 he was appointed research associate in medicine at the New York University School of Medicine and there subsequently became assistant professor of biochemistry (1945), professor of pharmacology (1946), professor of biochemistry (1954), and chair of the department of biochemistry. In 1956, he became an American citizen. He was elected to both the United States National Academy of Sciences and the American Academy of Arts and Sciences in 1957. In 1959, Ochoa and Arthur Kornberg were awarded the Nobel Prize for Physiology or Medicine "for their discovery of the mechanisms in the biological synthesis of ribonucleic acid and deoxyribonucleic acid". He was elected to the American Philosophical Society in 1961. Ochoa continued research on protein synthesis and replication of RNA viruses until 1985, when he returned to now democratic Spain where he was a science advisor. Ochoa was also a recipient of U.S. National Medal of Science in 1978. Severo Ochoa died in Madrid, Spain on 1 November 1993. Carmen García Cobián had died in 1986. Long after his death, Spanish actress Sara Montiel claimed that she and Severo Ochoa were involved in a romantic relationship in the 1950s, as stated in an interview in Spanish newspaper El País: "The great love of my life was Severo Ochoa. But it was an impossible love. Clandestine.
Amid renewed rumours of an impending Rhodesian UDI, Smith travelled to meet Wilson in London at the start of October 1965, telling the press that he intended to resolve the independence issue once and for all. Both the British and the Rhodesians were surprised by the large numbers of Britons who came out to support Smith during his visit. Smith accepted an invitation from the BBC to appear on its Twenty-Four Hours evening news and current affairs programme, but Downing Street blocked this at the last minute. Following largely abortive talks with Wilson, the Rhodesian prime minister flew home on 12 October. Desperate to avert UDI, Wilson travelled to Salisbury two weeks later to continue negotiations. During these discussions, Smith referred to the last resort of a UDI on many occasions, though he said he hoped to find another way out of the quandary. He offered to increase black legislative representation by expanding the electorate along the lines of "one taxpayer, one vote"—which would enfranchise about half a million, but still leave most of the nation voteless—in return for a grant of independence. Wilson said this was insufficient, and countered that future black representation might be better safeguarded by Britain's withdrawal from the colonial government of the power it had held since 1923 to determine the size and makeup of its parliament. The Rhodesians were horrified by this prospect, particularly as Wilson's suggestion of it seemed to them to have removed the failsafe alternative of keeping the status quo.
Additional records indicate that distinct morphological forms occur in anthropogenic habitats. A granulose form (formerly known as Xanthoria aureola) has been recorded predominantly on roofs in southeastern England.
Tissue engineering aims to replace lost or damaged tissues within the body. The success of such efforts has depended greatly upon the ability to direct cell behavior and encourage regeneration of tissues. A key method of doing so utilizes ECM-derived ligands such as RGD to control cellular responses to a biomaterial, such as attachment, proliferation, and differentiation.
An example of contemporary art is the heating plant in Corso Ferrucci, which has been covered with aluminium panels. Another building (19th century), now abandoned, is the former Westinghouse factory of train brakes situated in Via Borsellino. The residential and business zone of the district sprawls westward, beyond the former—now demolished—customs wall (cinta daziaria), which previously separated the city from the mainly rural landscape that marked the outskirts of Turin until the late 19th century. Urban planning outside the local city gate (so-called barriera di San Paolo) led to the construction of an industrial and working-class neighbourhood in the early 20th century, although factories have long been discontinued, torn down or converted to other uses nowadays. Together with San Paolo district, Cenisia hosts an extensive street market along Corso Racconigi, which is locally known as the longest street market in Europe.
Sources: en.wikipedia.org
== Gaiden 2 == The Gaiden 2 (外伝2) series, released between December 1999 and July 2000, adapted the novels Spiral Labyrinth (1–4) and part of Star Crusher (27–28), as well as the original stories "The Mutineer" (15–18), "The Duellist" (19–22) and "The Retriever" (23–26).
== Histatin 5 == Histatin 5 is the protein that is associated with the most antifungal function. The antimicrobial activity is concentrated in a region known as the functional domain. An example of its antimicrobial activity is its mechanism of action against C. albicans. The peptide is consumed by the cell and it causes ATP efflux and the production of reactive oxygen species.
The decrease in BMD during elagolix therapy may not be fully reversible with discontinuation, as only partial recovery was observed 12 months after discontinuation of therapy. The cause of the decrease in BMD with elagolix is estrogen deficiency, and is analogous to that associated with postmenopause. The consequences of the effects of elagolix on BMD are unknown, but may be an increase in the risk of bone loss and fractures. This is why the duration of use of elagolix should be limited. In women with risk factors for bone loss and osteoporosis, such as a history of low-trauma fracture, assessment of BMD may be considered. Elagolix should not be used in premenopausal women with known osteoporosis. Supplementation with calcium and/or vitamin D during treatment with elagolix has not been studied, but may be beneficial for helping to maintain bone health. Elagolix decreases the amount, intensity, and duration of menstrual bleeding. Amenorrhea, the cessation of menstruation, was observed in 4 to 17% of women with 150 mg once per day and in 7 to 57% of women with 200 mg twice per day, compared to less than 1% of women given placebo. The decreased menstrual bleeding caused by elagolix may impede the ability to recognize pregnancy in a timely manner. Based on its mechanism of action, elagolix may increase the risk of miscarriage in early pregnancy, and so should be discontinued if pregnancy occurs. If pregnancy is suspected, pregnancy testing can be performed.
Lancashire Police confirm the body found in the River Wyre the previous day is that of Nicola Bulley. 21 February – A planned 48-hour strike by nurses is called off to allow the Royal College of Nursing and Department of Health and Social Care to enter into renewed negotiations. The BMA maintains that junior doctor's pay has been cut by 26% since 2008 after inflation is considered. The UK Government recommends a 3.5% pay rise for public sector workers in England, below the rate of inflation. 22 February – Following a trial at Winchester Crown Court, Shaye Grove, 27, a woman obsessed with serial killers, is sentenced to life imprisonment with a minimum of 23 years for the murder of her boyfriend, who she stabbed to death in July 2022. 23 February – Figures produced by the Office for National Statistics show school absences in England remain above their pre-COVID levels, with 25.1% of pupils regularly absent during the autumn term of 2022 compared to 13.1% in autumn 2019. 24 February – The British Medical Association announces that junior doctors in England will begin a three-day strike on 13 March.
All triterpenoids are synthesized via the cyclization of the C30 isoprenoid chain, squalene. Eukaryotes use oxidosqualene cyclase and several other enzymes to create the tetracyclic skeleton found in steroids, a process that requires molecular oxygen. Bacteria use a similar enzyme (shc) to create the pentacyclic hopanoid precursor, diploptene; however, this biosynthesis does not require oxygen. It was recently discovered that tetrahymanol-producing bacteria form diploptene using shc then elongate the final cyclopentane into a fifth ring using tetrahymanol synthase (ths). It is unknown whether bacteria modify diploptene into other hopene molecules before creating tetrahymanol. It has also been found with a methylation at the C-3 site. Eukaryotes that live in anaerobic environments cannot synthesize their own sterols because of a lack of molecular oxygen. These organisms can gain sterols through predation. However, there can be times of sterol starvation. Tetrahymanol biosynthesis does not require oxygen, and can substitute readily for sterols. It is hypothesized that ciliates synthesize tetrahymanol in response to lack of oxygen and exogenous sterols. The gene for tetrahymanol synthase was found in the genomes of many genera of alpha-, delta-, and gammaproteobacteria, including Rhodopseudomonas, Bradyrhizobium and Methylomicrobium.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.